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Abstract Study design A comprehensive systematic
review of the literature. Objectives To assess the modern
literature on the use of polyethylene mesh-contained
morcelized allograft (PMCMA) bone for spinal fusion and
vertebral compression fracture management. Summary of
background data There are presently no systematic
reviews of PMCMA. Methods A systematic literature
review was performed within three databases (OVID,
PubMed, and Google Scholar) using the following keyword
search terms: vertebroplasty, kyphoplasty, vertebral com-
pression fracture, percutaneous, polyethylene mesh, and
osteoporosis. Results The initial search identiﬁed 764
items, from which two pertinent technique-based articles
were identiﬁed. There were no published scientiﬁc peer-
reviewed or case series reporting the clinical results of
this technique. The use of PMCMA in the management
of vertebral compression fractures (VCFs) is similar to
vertebroplasty and kyphoplasty. This novel, percutaneous
system uses the properties of granular mechanics to
establish a conforming, semirigid graft that is purport-
edly capable of withstanding physiologic loads.
Discussion PMCMA is a novel percutaneous technology
for the management of VCF and possibly for use as a
conforming interbody graft. The available published liter-
ature lacks outcome data of the use of PMCMA. Careful,
independent research is needed to assess the viability of
this technology and its long-term results.
Keywords Vertebral compression fracture 
Vertebroplasty  Kyphoplasty  Percutaneous 
Polyethylene mesh  Osteoporosis
Abbreviations
PMCMA Polyethylene mesh-contained morcelized
allograft
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Introduction
Vertebral compression fractures (VCFs) represent a major
cause of morbidity in patients affected by osteoporosis. It is
estimated that about 700,000 patients suffer from VCFs
each year in the United States and, as the population ages,
the incidence is expected to rise accordingly [1, 2]. The
cost of osteoporotic fractures represents a substantial por-
tion of healthcare spending, with a reported cost of over
$13.8 billion in 1995 [3]. Out of that total, osteoporotic
VCFs are believed to account for $700 million per year [1].
Traditional management of symptomatic VCFs has
involved a combination of analgesics, bed rest, orthotic
bracing, and physical therapy [4–6]. Although these treat-
ments are generally effective, there are indeed cases that
require an alternative approach. In recent years, minimally
invasive surgical techniques such as vertebroplasty and
kyphoplasty have been developed; they are becoming
increasingly popular as management options for this
common condition. Vertebroplasty is performed in an
effort to stabilize the injured bone. It involves the percu-
taneous injection of bone cement, polymethyl methacrylate
(PMMA), into the injured vertebral body. This imparts
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therebypreventingfurthercompressionoftheaffectedvertebral
body [3, 7]. Kyphoplasty is a more recent percutaneous
technique that utilizes a pressurized, inﬂatable balloon tamp
to create a void within the vertebral body. This space is then
ﬁlled with PMMA [1, 2, 8]. Both techniques appear to be
effective, with a high percentage of patients (greater than
90%) reporting pain relief. Good functional outcomes are
generally observed as well, although kyphoplasty has been
more successful in the restoration of vertebral height and
kyphotic angle [3–12]. Despite these beneﬁts, both procedures
arenot without complications.
The Optimesh system was developed by Spineology, Inc.
(St. Paul, MN) and recently received FDA-approval as a
means for percutaneous vertebral augmentation (PVA). It
provides an alternative technique to stabilize and treat VCFs
that are refractory to conservative management options.
Methods and results
Three databases were searched (OVID, PubMed, and
Google Scholar), using varying combinations of the
following keywords or terms: vertebroplasty, kyphoplasty,
spine fracture, percutaneous, compression fracture, allo-
graft, and Optimesh. These searches resulted in 764, 271,
594, 253, 7, and 2 items. These items were manually sor-
ted. Only two items directly related to polyethylene mesh-
contained morcelized allograft (PMCMA) were found.
These two items were technique descriptions and lacked
clinical outcome data. The authors of both articles recog-
nized that the next step needed to better assess the role of
optimesh in the management of osteoporotic VCFs would
be a study of clinical outcomes.
Discussion
The Optimesh system utilizes a unique design. It uses a
mesh bag that is made from a woven biocompatible poly-
ester (Dacron). One important mesh characteristic is that it
is porous enough to allow ﬂuid transmission and possibly
vascular ingrowth. The pore size, however, is small enough
to prevent leakage of the granular bone graft material. It is
also capable of expanding upon injection to accommodate
for any irregularities in the size and shape of the cavity
generated during surgery [2, 13].
Technique description
The patient is placed prone and prepped in the usual sterile
fashion on a radiolucent table. Digital C-arm ﬂuoroscopy is
necessary for proper anatomical localization of the affected
VCF and for instrumentation of the vertebral body.
Next, the guide pin is advanced into the vertebral body
via a lateral extrapedicular approach. A dilator is placed
over the guide pin and advanced into the vertebral body.
Care should be made to ensure that the guide pin is not
inadvertently advanced as the dilator is delivered into the
VCF site.
Next, the access portal is placed over dilator. The dila-
tor-guide pin assembly is then removed. A drill is used to
initiate cavity creation. This initial space is subsequently
enlarged with shaper-reamers. These expandable reamers
are used to create a cavity, which will ultimately contain
the morcelized graft ﬁlled mesh [1, 2, 13]. The reamers are
available in two sizes (5.8 or 10 mm diameter), and are
capable of producing a cavity of various diameters (14, 22,
and 25 mm diameter) [2].
This is followed by insertion of the woven Optimesh
implant sac. The tools and techniques required to implant
the graft material have been uniquely developed. A bone
ﬁll-tube, which inserts into the mesh bag provides a
channel for delivery of graft material. A bone push-rod ﬁts
into the ﬁll tube to both deliver and gradually compact the
graft material [1, 2]. In this manner, the sac is densely ﬁlled
with morcelized bone graft. With the bone graft location
conﬁrmed with ﬂuoroscopy, the instruments are removed.
The wounds are irrigated and subsequently closed.
Comparison to vertebroplasty and kyphoplasty
Compression of the paste-like bone graft preparation dur-
ing delivery causes exudation of the liquid component into
the surrounding porous bone. This leaves only the morc-
elized graft behind in the mesh-containment bag. During
this maneuver, the physical properties of the graft prepa-
ration change from that of a semisolid paste to a solid that
more closely mimic bone [2, 13]. Furthermore, this is
achieved without the risk of high-pressure injection that is
needed to insert PMMA. Another advantage over PMMA
is that the porous graft containment system has the
potential to be both osteoconductive and osteoinductive
[1, 21 3 ].
Optimesh is intended to provide a minimally invasive
surgical option to treat various forms of intraosseous ver-
tebral insufﬁciency, most commonly osteoporotic fractures.
Although clinical studies remain to be done, there appear to
be several perceived advantages to Optimesh over verteb-
roplasty/kyphoplasty in regards to complication avoidance.
Known risks associated with the use of vertebroplasty and
kyphoplasty include PMMA emboli, neurological com-
pression from intracanal cement leak, and foreign body
reaction [1, 2, 4–6, 9, 10].
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kyphoplasty are directly related to the use of PMMA.
Leakage of cement into the venous system has been
reported and may lead to pulmonary embolism, pulmonary
cement embolism, or cerebral vascular cement embolism
[1, 2, 4–6]. Neurological damage has also been reported.
Acute paraplegia from cement leakage compressing the
spinal cord has been reported [1, 2, 4, 5]. In addition, the
modulus of elasticity of PMMA in the treated level causesa
mismatch between it and the adjacent untreated levels. The
transition zone between treated and unreated levels causes
a so-called stress-riser effect, which has been through to
result in an increased incidence of adjacent level com-
pression fractures [9, 10]. Reports of adjacent fractures for
vertebroplasty have been reported to be between 12% and
52%, and between 3% and 29% for kyphoplasty [1, 6, 9].
Foreign-body reactions to PMMA have also been
reported [5]. Another criticism of the use of PMMA in
close proximity to the spinal cord is the heat released
during the exothermic reaction with cement curing [2, 5].
Although there is experimental evidence in animal models
to show the potential for neural tissue damage due to heat,
there has not been a reported case of this complication in
humans at the time of this writing [2, 5]. It should be noted
that reports of poor outcome for both vertebroplasty and
kyphoplasty ﬂuctuate greatly.
The material and biological characteristics of morcel-
ized bone are among the major reasons for the perceived
advantages of Optimesh. Compressed allograft bone can be
expected to more closely mimic the physical properties of
the surrounding native bone [1, 2]. If the stiffness of ver-
tebral bodies inﬁltrated with PMMA is in fact the cause of
an increased risk of subsequent VCF, the use of bone as
graft material may be useful in adjacent vertebrae fracture
risk reduction. Due to the porous nature of the woven mesh
bag and the morselized bone, it is conceivable that revas-
cularization may occur through and around the graft [2].
Proposed clinical indications
The criteria for the application of Optimesh for PVA have
been described previously [1]. The major indication is
VCFs with pain [1, 2]. Although it is not currently
approved for interbody use, it has been anecdotally used to
effect interbody fusion for the treatment of degenerative
disk disease [13]. The complete list of indications and
contraindications described by Chiu and Stechison [1]i sa s
follows:
Indications
1. Management of painful osteoporotic or posttraumatic
VCFs.
2. Intractable, focal band-like radicular pain that is worse
with weight bearing and is relieved with rest or in a
recumbent position.
3. Pain refractory to analgesics and narcotics.
4. Osteoporosis, aggressive hemangioma, metastatic
disease, osteogenic imperfecta, trauma, or vertebral
osteonecrosisresultinginapainfulcompressionfracture.
5. For the management of chronic nonunion following
traumatic vertebral body fractures
6. Internal stabilization of unstable posttraumatic VCFs.
7. Management of multiple compression fractures in a
patient with poor pulmonary reserve.
Absolute contraindications
1. Patients with painless asymptomatic stable VCFs.
2. Massive ‘‘burst’’ osteoporotic or nonosteoporotic
fractures.
3. Patients with fracture(s) that are clearly responding to
medical therapy.
4. Osteomyelitis of target vertebra.
5. Prophylactic treatment with no evidence of fracture.
6. Uncorrected coagulation/bleeding disorder.
Relative contraindications
1. Medically high-risk or unstable patient.
2. Patients with retropulsed bone causing spinal canal
compromise of greater than 20%.
3. Restless patient (unable to lie prone for the entire
procedure under IV conscious sedation).
4. Patient with pain due to herniated spinal disk, facet
arthropathy, spinal stenosis, or other degenerative
condition.
5. Pathological fracture with tumor signiﬁcantly extend-
ing into the spinal canal [1].
Clinical outcomes
Optimesh has been recently approved for use. So far, no
large clinical trials have been reported to date. However,
several successful cases have been reported. Chiu and
Stechison reported three successful procedures leading to
almost immediate postoperative pain reduction [1].
All three patients were of age greater than 70 years, had
fractures at different levels, and received conscious seda-
tion and local anesthesia [1]. A CT scan performed seven
weeks post-operatively suggested osteointegration at the
vertebral body-graft interface in one patient [1].
Modiﬁcations to the procedures in kyphoplasty and
vertebroplasty may reduce the problems associated with
the use of PMMA. The use of calcium phosphate as a graft
material has been demonstrated to be osteoconductive [14].
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[14].
Further evidence in material science and animal studies
support claims that the compaction of a wet granular
material such as morselized bone results in a phase change
to a more stable solid form [13, 15]. The characteristics of
this phase change can be likened to the change of proper-
ties of dry sand to the properties of wet, packed sand, such
as is observed in a sandcastle. This is largely due to
increased crowding of particles [15].
There has been little discussion in the literature about
the cost effectiveness of surgical management of VCFs,
and much of the existing discussion is contradictory. More
has been published about the cost effectiveness of verteb-
roplasty than about other techniques. Although surgery
often leads to pain relief where medication has failed,
many authors have reached no conclusion about the cost
beneﬁt of any procedure. Danish researchers have indicated
that the cost of vertebroplasty is offset by the reduction in
future hospital visits [16].
Although there is considerable excitement surrounding
Optimesh, the data in case reports are not enough to fully
assess the outcomes. The elimination of PMMA cement
will likely reduce the incidence of several known compli-
cations. It is not possible however, to predict if other
problems will be generated through the use of Optimesh.
Pulmonary thromboemboli and fat emboli have been
recorded in vertebroplasty and kyphoplasty, and there is
concern that the reaming process and the compacting steps
used in Optimesh application may promote the dislodging
of bone marrow, which could hypothetically amplify this
problem [2]. Additionally, the high degree of ﬂuctuation in
the frequency of adjacent compression fractures in both
vertebroplasty and kyphoplasty show that the variables
leading to this complication, despite many arguments
related to vertebral stiffness, have not been completely
assessed.
Conclusions
Optimesh is a new technology. Although a few successful
cases have been reported, these do not constitute a statis-
tically signiﬁcant sample set to make any deﬁnitive
statements about the safety and general outcomes follow-
ing PMCMA application. However, given both the initial
successes seen in some patients and the potential for further
beneﬁt, additional investigation into both short-term and
long-term patient outcomes is warranted.
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